Stock Track | Beta Bionics Soars 19% After Hours on Strong Q3 Results and Raised Guidance

Stock Track10-29

Shares of Beta Bionics Inc. (NASDAQ: BBNX) surged 19.44% in after-hours trading on Tuesday following the release of the company's third-quarter 2025 financial results, which exceeded analyst expectations and prompted a raise in full-year guidance.

The medical device company, known for its iLet bionic pancreas system, reported a narrower-than-expected loss of $0.33 per share, beating the analyst consensus estimate of $0.44 per share. This represents a significant improvement from the $1.46 per share loss reported in the same quarter last year. Revenue for the quarter came in at $27.3 million, a 63% increase year-over-year and surpassing the analyst estimate of $23.97 million.

Beta Bionics' strong performance was driven by robust growth in both its Durable Medical Equipment (DME) and Pharmacy Benefit Plan (PBP) channels. The company also received Special 510(k) clearance for updates to its iLet device on September 29, 2025, potentially contributing to investor optimism. In light of these results, Beta Bionics raised its full-year 2025 revenue guidance to over $96.5 million, up from the previous range of $88 million to $93 million. The company also increased its estimated gross margin forecast to 54-55%, up from 52-55% previously.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199361653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199361653","market":"sg","top_or_hot":-1,"title":"Stock Track | Beta Bionics Soars 19% After Hours on Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of Beta Bionics Inc. (NASDAQ: BBNX) surged 19.44% in after-hours trading on Tuesday following the release of the company's third-quarter 2025 financial results, which exceeded analyst expectations and prompted a raise in full-year guidance.</p>\n\n<p>The medical device company, known for its iLet bionic pancreas system, reported a narrower-than-expected loss of $0.33 per share, beating the analyst consensus estimate of $0.44 per share. This represents a significant improvement from the $1.46 per share loss reported in the same quarter last year. Revenue for the quarter came in at $27.3 million, a 63% increase year-over-year and surpassing the analyst estimate of $23.97 million.</p>\n\n<p>Beta Bionics' strong performance was driven by robust growth in both its Durable Medical Equipment (DME) and Pharmacy Benefit Plan (PBP) channels. The company also received Special 510(k) clearance for updates to its iLet device on September 29, 2025, potentially contributing to investor optimism. In light of these results, Beta Bionics raised its full-year 2025 revenue guidance to over $96.5 million, up from the previous range of $88 million to $93 million. The company also increased its estimated gross margin forecast to 54-55%, up from 52-55% previously.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Beta Bionics Soars 19% After Hours on Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Beta Bionics Soars 19% After Hours on Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-29 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Beta Bionics Inc. (NASDAQ: BBNX) surged 19.44% in after-hours trading on Tuesday following the release of the company's third-quarter 2025 financial results, which exceeded analyst expectations and prompted a raise in full-year guidance.</p>\n\n<p>The medical device company, known for its iLet bionic pancreas system, reported a narrower-than-expected loss of $0.33 per share, beating the analyst consensus estimate of $0.44 per share. This represents a significant improvement from the $1.46 per share loss reported in the same quarter last year. Revenue for the quarter came in at $27.3 million, a 63% increase year-over-year and surpassing the analyst estimate of $23.97 million.</p>\n\n<p>Beta Bionics' strong performance was driven by robust growth in both its Durable Medical Equipment (DME) and Pharmacy Benefit Plan (PBP) channels. The company also received Special 510(k) clearance for updates to its iLet device on September 29, 2025, potentially contributing to investor optimism. In light of these results, Beta Bionics raised its full-year 2025 revenue guidance to over $96.5 million, up from the previous range of $88 million to $93 million. The company also increased its estimated gross margin forecast to 54-55%, up from 52-55% previously.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBNX","symbol_name":"Beta Bionics, Inc.","start_time":0,"source_url":"","article_id":"1199361653","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199361653","pubTimestamp":1761683542,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Beta Bionics Inc. (NASDAQ: BBNX) surged 19.44% in after-hours trading on Tuesday following the release of the company's third-quarter 2025 financial results, which exceeded analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBNX":"Beta Bionics, Inc."},"translate_title":"个股追踪|Beta Bionics盘后大涨19%，第三季度业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBNX":1},"content_text":"Shares of Beta Bionics Inc. (NASDAQ: BBNX) surged 19.44% in after-hours trading on Tuesday following the release of the company's third-quarter 2025 financial results, which exceeded analyst expectations and prompted a raise in full-year guidance.\nThe medical device company, known for its iLet bionic pancreas system, reported a narrower-than-expected loss of $0.33 per share, beating the analyst consensus estimate of $0.44 per share. This represents a significant improvement from the $1.46 per share loss reported in the same quarter last year. Revenue for the quarter came in at $27.3 million, a 63% increase year-over-year and surpassing the analyst estimate of $23.97 million.\nBeta Bionics' strong performance was driven by robust growth in both its Durable Medical Equipment (DME) and Pharmacy Benefit Plan (PBP) channels. The company also received Special 510(k) clearance for updates to its iLet device on September 29, 2025, potentially contributing to investor optimism. In light of these results, Beta Bionics raised its full-year 2025 revenue guidance to over $96.5 million, up from the previous range of $88 million to $93 million. The company also increased its estimated gross margin forecast to 54-55%, up from 52-55% previously.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199361653","isCrawlerRequest":true}